noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Financial Services

Newmark Group Inc.

Newmark Arranges Sale of Golden Triangle Logistics Center in North Las[...]
Valeas Capital Partners Management LP

Suntera strengthens UK fund services proposition with acquisition of[...]
PHFA - Pennsylvania Housing[...]

11/11 PHFA Releases 2027/2028 Qualified Allocation Plan for Low-Income[...]

Economy, Business and Finance

Grove Street Advisors LLC

10/29/2026 | Press release | Archived content

Third Rock Ventures exits Merida Biosciences to Eli Lilly

Merida Biosciences is a biotechnology company developing precision therapeutics designed to selectively degrade disease-causing autoantibodies for patients with serious autoimmune and allergic diseases.

Eli Lilly agreed to acquire Merida for up to $2.875 billion in cash, gaining a platform with potential application across a broad range of antibody-driven conditions, including Graves' disease, thyroid eye disease, and food allergy. Merida's lead program, MER511, has demonstrated early Phase 1 data in Graves' disease.

GroveStreet first became a Third Rock Ventures LP in 2007. Read more here.

Learn more about us or reach out to schedule a meeting.

Grove Street Advisors LLC published this content on October 29, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 11, 2026 at 18:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format